1. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma;Witzig;J Clin Oncol,2002
2. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory non-Hodgkin's follicular lymphoma;Witzig;J Clin Oncol,2002
3. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial;Wiseman;Blood,2002
4. Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non- Hodgkin's lymphoma;DeNardo;J Clin Oncol,1998
5. Zevalin radioimmunotherapy (RIT) is safe and effective in geriatric patients with low grade, follicular or CD20+ transformed (LG/F/T) non-Hodgkin lymphoma (NHL);Emmanouilides;Proc Am Soc Clin Oncol,2001